Digitalis Ventures
Venture capitalNew York · Seed–Late Stage · 18 people tracked
Also known as DIGITALIS VENTURES, LLC
Investment thesis
Digitalis Ventures focuses on solutions to unmet needs in biomedicine and health. On the human health side, it backs biotechnology companies leveraging breakthrough science, as well as companies building novel technology-enabled solutions that improve access to care and health outcomes while lowering costs for individuals and the broader healthcare system. Through its Companion Funds, the firm also invests in companies applying science, technology, and design to improve animal health. Digitalis emphasizes a multidisciplinary team approach to solving complex problems and shares its investment thinking publicly through the Digitalis Notebook, alongside its related efforts at Digitalis Commons and Digitalis Labs.
Source: firm website, verified Aug 11, 2026.
Team · 18 people
from the firm's website & public directories
What they invest in
from 35 of 56 portfolio companiesBiotech ×27Healthtech ×17Medical Devices ×11Deep Tech ×8AI & Machine Learning ×7Digital Health ×6FoodTech ×2InsurTech ×2
HQs:United States×26Australia×1Canada×1Germany×1
Investments · 56 tracked
founders shown can be your intro pathBy year:2025 · 22024 · 22021 · 22017 · 12016 · 12015 · 19 dated
Faeth Therapeutics develops PIKTOR, an oral multi-node inhibitor targeting the PI3K/AKT/mTOR pathway for cancer treatment, currently in clinical trials for endometrial and breast cancer.
BiotechDigital HealthMedical DevicesAustin, US
Anand Parikh(Executive Officer, Director, Promoter)Oliver Maddocks(Executive Officer, Director)
BoardAlex Morgan(Director)Jayson Dallas(Director)Robert Gould(Director)Stephen Hahn(Director)
Gallant develops regenerative medicine therapies for veterinary care, bringing treatments from laboratory research into clinical practice for pets.
BiotechHealthtechMedical DevicesSan Diego, US
Linda Black(Chief Executive Officer, Chief Financial Officer & Secretary)Aaron Hirschhorn(Executive Officer, Director)Davis Brimer(Executive Officer, Director)
BoardTeymour Boutros-Ghali(Director)Valentine Williams(DVM, MS, Diplomate ACVS)Aaron Schacht(Director)
Board seatMisti Ushio· per SEC Form D · $18M raise · filed Jul 2025
BiotechNew York, US
David Schubert(Executive Officer, Promoter)Joel Marcus(Director)Lindsay Rayle(Executive Officer, Promoter)Barbara Dalton(Director)Steve Gillis(Director)David Pompliano(Executive Officer)
Board seatMisti Ushio· per SEC Form D · $19.9M raise · filed Jan 2017
Sunnyvale, US
John Chen(Director)Bernard Lemaitre(Director)
BoardSrinivas Rao(Executive Officer, Director)Nobuyuki Kambe(Director)
Board seatMisti Ushio· per SEC Form D · $600K raise · filed Jan 2016
Remote patient monitoring software platform utilizing sensors, predictive analytics, and machine learning for real-time personalized care.
HealthtechNew York, US
Charles Herman(Executive Officer, Director)Meir Akkerman(Director)Eran Ofir(Executive Officer, Director)
BoardAndrew Gianonne(Director)Christopher Geczy(Director)
Board seatDrew TaylorAmit Bansal· per SEC Form D
Alcea Tx develops an immune-tolerance restoration technology that targets Treg cells to reset immune homeostasis in the lungs, with a lead asset aimed at asthma and pulmonary viral infections such as influenza and SARS-CoV2.
BiotechHealthtech
Alpha-9 Oncology develops radiopharmaceuticals for cancer treatment, with a portfolio of molecules in clinical and preclinical development.
BiotechDigital HealthMedical DevicesVancouver, CA
François Bénard(MD)Kuo-Shyan Lin(PhD)David Perrin(PhD)
Alterome is a clinical-stage precision oncology company developing small molecule therapies targeting mutant KRAS and AKT E17K in cancers including non-small cell lung, pancreatic, colorectal, endometrial, and breast cancer.
BiotechHealthtechMedical DevicesSan Diego, US
Eric A. Murphy(Executive Officer, Director, Promoter)Ryan B. Corcoran(Director, Promoter)
BoardThilo Schroeder(Director)Carl Gordon(Director)Arjun Goyal(Director)
Ascend is a gene-to-GMP development partner that helps life-science companies advance advanced therapy products from the research bench through clinical stages.
BiotechHealthtechMedical DevicesMunich, DE
B5 Genomics offers the Benthic Analysis Platform, software that converts microarray and sequencing data (short-read and long-read) into high-resolution genotyping and variant calls for complex genomic regions such as HLA, KIR, and the MHC.
AI & Machine LearningBiotechHealthtech
Bonum Therapeutics is an early-stage biotechnology company.
BiotechSeattle, US
John Mulligan(Executive Officer, Director, Promoter)Neela Patel(Executive Officer)Diane Hollenbaugh(Executive Officer)
BoardSamuel Bjork(Director)Monique Schiersing(Director)John McKearn(Director)
Elegant Bio develops DNA synthesis technology and services, offering ENFINIA™ DNA synthesis at scale for biotech and research applications.
BiotechDeep TechSan Carlos, US
Matthew Hill(Executive Officer, Director)Jonathan Sheena(Director)
BoardPeter Zhou(Director)Cain McClary(Director)
Elemental Machines builds IoT sensors, software, and data science tools that unify data streams from lab and manufacturing environments to monitor conditions and improve operational efficiency.
AI & Machine LearningBiotechHardwareHealthtechIoTCambridge, US
Una Ryan(Director)Sridhar Iyengar(Executive Officer, Director)Jeff Klemens(Director)Sam Bjork(Director)Sonny Vu(Director)
BoardGaurav Tewari(Director)
Epibiologics develops protein degradation medicines using protein sciences and antibody engineering capabilities.
BiotechMedical DevicesSan Mateo, US
Jason Coloma(Director)Ann Lee-Karlon(Executive Officer, Director)Samuel Bjork(Director)Alexandra Cantley(Director)Mitchell Mutz(Executive Officer, Director)Seiji Miyahara(Director)
Expressable provides online speech therapy delivered by licensed speech therapists for children and adults through live 1-on-1 sessions conducted from home, paired with weekly practice activities and caregiver support.
Digital HealthHealthtechSaaS
HealthtechMiami Lakes, US
Carlos D. Bustamante(Executive Officer, Director)Alexander Ioannidis(Director)Arthur Polk(Executive Officer)
BoardWale Ayeni(Director)Mohit Kaushal(Director)Nicholas Katsanis(Director)
Portfolio company acquired by Roche.
BiotechSeattle, US
Mitchell Mutz(Director)Nicholas Walrod(Director)John Mulligan(Executive Officer, Director, Promoter)Karl Handelsman(Director)
BoardJohn McKearn(Director)
BiotechCambridge, US
Daniel J Mandell(Executive Officer, Director)Tracey Lodie(Executive Officer)Christopher Gregg(Director)
BoardMing Fang(Director)Bruce Beutel(Director)Dan Becker(Director)
Helm Health provides benefit design and member engagement tools for health plans, incorporating cost and quality data into coverage decisions, bundling claims into transparent pricing, and offering provider search functionality.
Enterprise SoftwareHealthtechInsurTechSan Francisco, US
Kingdom Supercultures develops functional health ingredients using natural microbes, aiming to improve consumer health.
BiotechFoodTechHealthtechNew MaterialsWellness & Fitness
Functional nutrition company making supplements for dogs.
St Louis, US
Patrick M Barron(Manager / Member)
Onc.AI develops the Onclara platform, which uses oncology real-world data to build predictive and prognostic AI models for cancer decision-making.
AI & Machine LearningBiotechDigital Health
Novel antibody-based therapeutics platform for animal health.
Positive Development provides autism therapy and developmental care services for neurodivergent children and their families.
Digital HealthHealthtechMedical DevicesMental HealthMclean, US
Mike Suiters(Executive Officer, Director)Nick Whitehead(Director)
BoardAdam Seabrook(Director)Daniel Gebremedhin(Director)John Banta(Director)Brenton Fargnoli(Director)
Protego Bio develops first-in-class small molecule pharmacological chaperones designed to restore protein function and treat protein misfolding diseases such as cardiomyopathy and AL amyloidosis.
AI & Machine LearningBiotechDeep Tech
Transforming the way people navigate the gaps between health care and social care, focused on reaching people on Medicaid/Medicare.
Minneapolis, US
Early-stage company from the Archer Seed Fund that received follow-on funding in outside-led rounds.
Philadelphia, US
Mark Hefferman(Executive Officer, Director)Tadataka Yamada(Director)Nancy Hong(Director)
BoardAditya Kohli(Director)Patrick Heron(Director)Cindy Cole(Director)
BiotechWaltham, US
Carl M. Berke(Director)Nancy Hong(Director)Ellen E. Sheets(Executive Officer, Director)
Switch Therapeutics develops RNA interference (RNAi) therapeutic applications targeting central nervous system diseases, leveraging research from Caltech, Harvard Medical School, and City of Hope.
AI & Machine LearningBiotechDeep TechMedical DevicesSouth San Francisco, US
Kevin Zhang(Director)Dylan Morris(Director)Si-Ping Han(Secretary)Deepshikha Datta(Chief Executive Officer and President)
BoardAlicia Irurzun-Lafitte(Director)
Terray Therapeutics develops small molecule drugs using its EMMI platform, which combines proprietary hardware, custom-generated datasets, and AI models for drug discovery.
AI & Machine LearningBiotechDeep Tech
Terraytx develops therapeutics and approaches to drug discovery; the company emphasizes collaborative, multidisciplinary research to advance scientific innovation in the life sciences space.
AI & Machine LearningBiotechDeep Tech
BoardChris PicardoDusan PerovicSid ShenaiSamuel BjorkBassil Dahiyat, Ph.D.Wendy Young, Ph.D.
Varda industrializes low Earth orbit by manufacturing pharmaceuticals and other specialized products in space, then returning them to Earth via reusable reentry capsules.
BiotechDeep TechSpace TechEl Segundo, US
Will Bruey(Founder)Delian Asparouhov(Founder)
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Exits · 2
IPOs and acquisitions across the tracked portfolioFaeth TherapeuticsNASDAQ: FTHGood Therapeuticsacq. by Roche
Portfolio news
latest coverage across their companiesClasp · fortuneindia.com · Jul 17, 2026
Alterome · geekwire.com · Jul 13, 2026
Elegen · businesswire.com · Jan 27, 2026
Positive Development · modernhealthcare.com · Jan 16, 2026
Frequently asked questions
- What stage does Digitalis Ventures invest at?
- Digitalis Ventures invests at the Seed, Series A, Late Stage stages.
- What is Digitalis Ventures's typical check size?
- Digitalis Ventures typically writes checks of $100K – $10M.
- What sectors does Digitalis Ventures focus on?
- Digitalis Ventures focuses on Biotech, Digital Health, Healthtech, Longevity, Medical Devices.
- Where is Digitalis Ventures located?
- Digitalis Ventures is headquartered in New York, US.
- Does Digitalis Ventures lead rounds?
- Yes, Digitalis Ventures leads investment rounds.
Images
Co-investors · 29
RiverVest Venture Partners is a life sciences venture capital firm that invests in biotechnology and medical companies, working with entrepreneurs to advance therapeutic and medical innovations.
F-Prime Capital Partners is a venture capital firm whose team of scientists, engineers, physicians, operators, and investors supports companies in scaling and accelerating growth.
Atlas Venture is a life sciences venture capital firm with three decades of experience investing in and building biotech and medical innovation companies, including startups launched from its own incubator.
Founder Collective is an early-stage venture capital firm focused on seed and pre-seed investments across all sectors.
Madrona Venture Group is an early-stage venture capital firm that backs founding teams at seed, early, and acceleration stages, primarily in Seattle, the Bay Area, and beyond.
BOLD Capital Partners is a venture firm backing entrepreneurs across a range of technical and scientific domains, with a dedicated BOLD Longevity Growth practice.
Vivo Capital is a global healthcare-focused investment firm operating a multi-strategy platform spanning venture capital, private equity, and public equity. It aims to expand healthcare access and drive innovation through its 'Ecosystem Strategy.'
Roche Venture Fund is a corporate venture arm that invests in early-stage biotech and diagnostics companies across more than 10 countries, with a portfolio exceeding 30 portfolio companies. The fund is headquartered in Basel, Switzerland.
GV (formerly Google Ventures) is a venture investment firm that backs founders across many industries, aiming to build long-term relationships and support companies across multiple stages and milestones.
Polaris Partners is a venture capital firm that partners with biotech and healthcare entrepreneurs to build transformational companies.
GutBrain Ventures is an early-stage technology venture capital firm led by investor and former entrepreneur Bob Davoli, who partners closely with founders and management teams to help build and scale high-growth software and technology companies.
Sofinnova Partners is a life sciences venture capital firm investing across the value chain from seed to later stage, with a focus on healthcare and sustainability. It backs companies in biopharma, medtech, digital medicine, agriculture and industrial processes.
▶17 more co-investors
Cambridge Innovation CapitalOmega Venture PartnersTechstarsInnovation EndeavorsPICUS CAPITALDN CapitalTwo Sigma VenturesWhat If VenturesArtis VenturesMPM BioImpact7wire VenturesAccess IndustriesQiming Venture PartnersConnecticut InnovationsParkwalk AdvisorsCodon CapitalSageview Capital
Firms observed investing alongside Digitalis Ventures, from public investor directories. Shared companies are the overlap with Digitalis Ventures's recorded portfolio.
Similar investors
GV (formerly Google Ventures) is a venture investment firm that backs founders across many industries, aiming to build long-term relationships and support companies across multiple stages and milestones.
5AM Ventures is a life science venture capital firm founded in 2002 that invests primarily in private therapeutic companies, with a focus on biopharmaceuticals, drug delivery technologies, and life science instruments.
Illumina Ventures is a venture investor focused on genomics and precision health, aiming to advance innovation and impact in human health.
JAZZ Venture Partners is a venture capital firm investing in companies at the intersection of technology, neuroscience, and human performance, spanning digital health, biosciences, and AI.
Novo Holdings is the holding and investment company that manages the assets of the Novo Nordisk Foundation, serving as controlling shareholder of Novo Nordisk and Novonesis. It invests in life science companies across all stages and manages a diversified portfolio of equities, bonds, real estate, infrastructure and private equity.